Trinity Biotech PLC (TRIB)
1.835
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 15:31
Trinity Biotech Enterprise Value: 118.15M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 118.15M |
| April 22, 2024 | 117.39M |
| April 19, 2024 | 117.21M |
| April 18, 2024 | 120.06M |
| April 17, 2024 | 118.54M |
| April 16, 2024 | 119.11M |
| April 15, 2024 | 121.21M |
| April 12, 2024 | 119.30M |
| April 11, 2024 | 118.15M |
| April 10, 2024 | 121.94M |
| April 09, 2024 | 120.64M |
| April 08, 2024 | 121.97M |
| April 05, 2024 | 123.88M |
| April 04, 2024 | 124.66M |
| April 03, 2024 | 125.74M |
| April 02, 2024 | 123.12M |
| April 01, 2024 | 122.74M |
| March 28, 2024 | 126.18M |
| March 27, 2024 | 123.88M |
| March 26, 2024 | 125.41M |
| March 25, 2024 | 128.85M |
| March 22, 2024 | 129.23M |
| March 21, 2024 | 130.38M |
| March 20, 2024 | 132.29M |
| March 19, 2024 | 131.91M |
| Date | Value |
|---|---|
| March 18, 2024 | 131.33M |
| March 15, 2024 | 133.82M |
| March 14, 2024 | 132.29M |
| March 13, 2024 | 133.05M |
| March 12, 2024 | 135.35M |
| March 11, 2024 | 133.44M |
| March 08, 2024 | 133.44M |
| March 07, 2024 | 133.44M |
| March 06, 2024 | 131.14M |
| March 05, 2024 | 128.47M |
| March 04, 2024 | 130.38M |
| March 01, 2024 | 130.38M |
| February 29, 2024 | 131.53M |
| February 28, 2024 | 132.29M |
| February 27, 2024 | 136.11M |
| February 26, 2024 | 136.11M |
| February 23, 2024 | 139.93M |
| February 22, 2024 | 133.78M |
| February 21, 2024 | 140.12M |
| February 20, 2024 | 146.81M |
| February 16, 2024 | 147.57M |
| February 15, 2024 | 145.68M |
| February 14, 2024 | 147.61M |
| February 13, 2024 | 151.20M |
| February 12, 2024 | 155.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
117.21M
Minimum
Apr 19 2024
752.21M
Maximum
Feb 16 2021
262.88M
Average
252.20M
Median
Enterprise Value Benchmarks
| Amarin Corp PLC | 32.53M |
| Avadel Pharmaceuticals PLC | 1.533B |
| DBV Technologies SA | -9.690M |
| Adaptimmune Therapeutics PLC | 129.51M |
| Akari Therapeutics PLC | 5.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.721M |
| Revenue (Quarterly) | 14.68M |
| Total Expenses (Quarterly) | 19.18M |
| EPS Diluted (Quarterly) | -0.875 |
| Gross Profit Margin (Quarterly) | 29.16% |
| Profit Margin (Quarterly) | -45.79% |
| Earnings Yield | -203.8% |
| Normalized Earnings Yield | -197.93 |